Supplemental Experimental Procedures
High bone mass (HBM) subjects carrying LRP5 mutations: The HBM study is a UKbased multi-centered observational study of adults with unexplained HBM identified by screening 335,115 DXA scans from 13 UK DXA databases from which 258 HBM probands with BMD Z-score ≥+3.2 were identified. All participants were clinically assessed by one doctor using a standardized structured history and examination questionnaire, after which total-body Lunar prodigy DXA scans were performed (Gregson et al., 2013; Gregson et al., 2012) . Written informed consent was collected for all, in line with the Declaration of Helsinki.
Participants were excluded if they were aged <18 years, pregnant, or unable to provide written informed consent for any reason. This study was approved by the Bath Multicenter
Research Ethics Committee (REC) and at each NHS Local REC. Cases with HBM LRP5 mutations were identified by targeted sequencing of exons 2-4 of LRP5 (i.e. the sites of previously described HBM cases). Primers are available upon request (Duncan et al., 2009 ).
Six autosomal dominant HBM cases from 3 kindreds participated in the follow-on study. All subjects underwent basic anthropometric measurements, fasting blood sampling and a DXA scan. Lunar measured body composition parameters were compared between 6 LRP5 HBM cases and 18 matched non-LRP5 HBM controls.
Genotyping: Subjects were genotyped using TaqMan® SNP Genotyping Assays as previously described (Vasan et al., 2011) .
Isolation, culture, and differentiation of human SVCs:
The SVC layer containing preadipocytes was separated from mature adipocytes following collagenase (Roche)digestion (1 mg/ml in Hanks' buffered salt solution) of WAT biopsies, and cultured in Dulbecco's modified Eagle's medium nutrient mixture F-12 Ham (DMEM-F12) supplemented with 10% foetal calf serum (FCS), 2 mM L-glutamine, 0.25 ng/ml fibroblast growth factor, 100 units/ml penicillin and 100 g/ml streptomycin, as previously described (Collins et al., 2010) .
For differentiation experiments, SVCs were grown to confluence in 6-well plates, and stimulated for 14 days with a standard adipogenic medium (DMEM-F12 containing 2mM glutamine, 17 M pantothenate, 100 nM human insulin, 0.1 M 3,3',5-triiodo-L-thyronine, 33
M biotin, 10 g/ml human transferrin and 1 M dexamethasone). For the first 5 days, 250
M 3-isobutyl-1-methylxanthine and 4 μM troglitazone were added to the adipogenic medium. For quantitative measurements of intracellular lipids, SVCs were grown to confluence and differentiated in type I collagen-coated 96-well plates for 16 days, then assayed using the AdipoRed adipogenesis assay reagent (Lonza) and a CytoFluor Multi-well Plate Reader series 4000 (PerSeptive Biosystems), according to manufacturers' instructions.
